| Date | Title | Description |
| 30.03.2026 | We’re exiting this tech stock to replenish our cash pile after our annual charity donation | - |
| 20.02.2026 | Curt Smith: Fighting blood cancer is easier with a group effort | - |
| 28.05.2025 | These biotech stocks will benefit as generative AI speeds up drug discovery, Jefferies says | - |
| 29.10.2024 | Tolerance Bio: $17.2 Million (Seed) Raised To Increase Healthspan By Manipulating Thymus Functions | Tolerance Bio, a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, announced the closing of its ov... |
| 20.10.2024 | Tolerance Bio: Pioneering the Future of Immune Health with $17.2 Million Seed Funding | In the world of biopharmaceuticals, innovation is the lifeblood. Tolerance Bio, a Philadelphia-based company, has just secured $17.2 million in seed funding. This financial boost is not just a number; it represents a beacon of hope for many... |
| 20.10.2024 | Tolerance Bio: $17.2 Million (Seed) Raised For Increasing Healthspan By Adjusting Function Of The Thymus | Tolerance Bio – a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance – announced the closing of its ... |
| 01.04.2024 | Впервые в мире почку свиньи изменили генетически и пересадили человеку. Теперь их можно массово пересаживать... | Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной свиньи. СМИ сообщают, что данная операция является прорывом в области ксенотрансплантации, когда органы, клетки или ткани пересаживаются из одн... |
| 17.08.2023 | The 30 young leaders who are forging a new future for the healthcare industry in 2023 | Your browser does not support the video element. This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
A new generation of leaders is transforming the healthcare industry.
They're developing ne... |
| 30.11.2022 | Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference | CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during... |
| 29.12.2021 | TalkPython: лучшие пакеты Python по итогам 2021 года | На КДПВ в гостях у TalkPython вы видите Гвидо ван Россума — создателя Python, Марка Шеннона, план ускорения Python в 5 раз за 4 года и, конечно, автора подкаста. А мы делимся подборкой пакетов Python, о которых шла речь в выпусках за уходящ... |
| 07.02.2020 | Beam Therapeutics raises $180M in IPO | The company had filed to go public in September, aiming at a $100 million IPO. J.P. Morgan, Jeffereies and Barclays acted as joint book runners.
Its last major financing before the IPO was a Series B funding round that it raised in March wo... |
| 07.02.2020 | Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered | - |
| 06.02.2020 | Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered | - |
| 06.02.2020 | Beam Therapeutics raises $180 million in IPO | Beam Therapeutics (BEAM), a Cambridge, Mass., genome-editing startup, raised $180 million in an initial public offering Wednesday after increasing the number of shares it offered to investors by 48 percent.
Unlock this article by subscribin... |
| 27.01.2020 | Gene editing biotech Beam Therapeutics sets terms for $100 million IPO | - |
| 30.09.2019 | Gene editing company Beam Therapeutics aims for $100M IPO | The company declined to comment because it is in a quiet period in connection with the filing.
Beam’s last major financing was a $135 million Series B funding round that it raised in March. It launched in May of last year with an $87 millio... |
| 07.05.2019 | Verve Therapeutics aims to tackle heart disease through gene editing | In terms of financing, the company has raised a $58.5 million Series A round, led by GV and with participation from biopharma venture capital firms ARCH Venture Partners, F-Prime Capital and Biomatics Capital.
“Our genetic understanding of ... |
| 07.03.2019 | Single-letter gene editing startup Beam Therapeutics raises $135M Series B round | The company launched last May, emerging from stealth mode with an $87 million Series A funding round led by ARCH and F-Prime.
Beam’s technology is designed to edit the genome at the letter of the single letter – A (adenine), G (guanine), T ... |
| 06.03.2019 | Gene editing startup Beam Therapeutics raises $135M Series B round | - |
| 06.03.2019 | Beam Therapeutics Secures $135M in Series B Financing | Beam Therapeutics, a Cambridge, Mass.-based biotechnology company developing precision genetic medicines through base editing, completed a $135m Series B financing.
Backers included new investors Redmile Group, Cormorant Asset Management, G... |
| 06.03.2019 | Term Sheet — Wednesday, March 6 | BAD MEDICINE
Medicine and money can be a dangerous combination. The rapid rise of health system venture capital funding is surfacing some thorny ethical dilemmas, according to a Healthcare Dive investigation.
Paid Content You can't secure w... |
| 06.03.2019 | Beam Therapeutics Secures $135 Million In Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the successful completion of a $135 million Series B financing. Proceeds from the fin... |
| 06.03.2019 | Beam Therapeutics Inks $135M in Series B |
CAMBRIDGE, MA, Beam Therapeutics announced the successful completion of a $135 million Series B financing.
>> Click here for more funding data on Beam Therapeutics
>> To export Beam Therapeutics funding data to PDF and Excel... |
| 06.03.2019 | Beam Therapeutics Secures $135 Million in Series B Financing to Advance Base Editing Platform and Expand Pipeline of Precision Genetic Medicines | - |
| 15.05.2018 | Term Sheet — Tuesday, May 15 | ALL BETS ARE ON
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
In a 6-3 ruling, The Supreme Court cleared the way for states to legalize sports betting, striking down a 1992 federal l... |
| 14.05.2018 | Beam Therapeutics Launches with $87M Series A |
CAMBRIDGE, MA, Beam Therapeutics is launching with up to $87 million in cumulative Series A funding for Beam and an affiliated entity.
>> Click here for more funding data on Beam Therapeutics
>> To export Beam Therapeutics f... |
| 14.05.2018 | Beam Therapeutics Raises up to $87M in Series A Financing | Beam Therapeutics, Inc., a Cambridge, MA-based developer of a suite of DNA base editing technologies for the treatment of human disease, raised up to $87m in Series A financing.
The round was led by F-Prime Capital Partners and ARCH Venture... |
| 14.05.2018 | Beam Therapeutics Founded by Gene Editing Pioneers to Create Precision Genetic Medicines with Base Editing | - |
| 14.05.2018 | Beam Therapeutics Raises $87M Series A | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Beam Therapeutics announced today that it is launching to develop precision genetic medicines that make edits to individual base pairs in the genetic code. Co-founded by scientific pioneers known for advan... |
| - | Beam Therapeutics raises $180M in IPO | A company developing means to edit genes at the single-letter level has raised nearly $200 million in its initial public offering.
Cambridge, Massachusetts-based Beam Therapeutics said Wednesday evening that it had priced its IPO at $180 mi... |
| - | Single-letter gene editing startup Beam Therapeutics raises $135M Series B round | A firm that launched last year to develop therapies using single-letter CRISPR/Cas9 gene editing has raised another round of financing.
Cambridge, Massachusetts-based Beam Therapeutics said Wednesday that it had closed a $135 million Series... |
| - | Gene editing company Beam Therapeutics aims for $100M IPO | A company developing a technology to edit genes at the single-letter level has filed to go public.
In an S-1 filing with the Securities and Exchange Commission Friday, Cambridge, Massachusetts-based Beam Therapeutics announced its planned $... |
| - | A lottery with lives hanging in the balance
Is peer review underrated?
Sign up for STAT China: Your guide to China’s emerging biotech market
Beam Therapeutics has a $180M IPO
An embassy's Dutch dr... | - |
| - | Verve Therapeutics aims to tackle heart disease through gene editing | Most gene therapies developed to date have gone after rare, inherited diseases. But a newly launched company is going after one of the most widespread ailments and causes of death on earth.
Cambridge, Massachusetts-based Verve Therapeutics ... |
